Zobrazeno 1 - 10
of 25
pro vyhledávání: '"Elisaveta Voynova"'
Autor:
Elisaveta Voynova, Damian Kovalovsky
Publikováno v:
Cells, Vol 10, Iss 11, p 2845 (2021)
Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling d
Externí odkaz:
https://doaj.org/article/1471f5ef444d4ee091b20c4a9d5d1c72
Autor:
Elisaveta Voynova, Nga Hawk, Francis A. Flomerfelt, William G. Telford, Ronald E. Gress, Jennifer A. Kanakry, Damian Kovalovsky
Publikováno v:
Cancers; Volume 14; Issue 3; Pages: 524
Cancers, Vol 14, Iss 524, p 524 (2022)
Cancers, Vol 14, Iss 524, p 524 (2022)
NK effector cells expressing a CAR construct may be used to target T-lineage markers. In this work, we compared the activity of a NK-specific CAR-NK and a CAR-T framework when expressed on NK effector cells to target CD3 and CD5 in T-cell malignancie
Autor:
Damian Kovalovsky, Elisaveta Voynova
Publikováno v:
Cells, Vol 10, Iss 2845, p 2845 (2021)
Cells
Cells
Chimeric antigen receptor (CAR) T-cell therapy was envisioned as a mechanism to re-direct effector T-cells to eliminate tumor cells. CARs are composed of the variable region of an antibody that binds a native cancer antigen coupled to the signaling d
Autor:
Elisaveta Voynova, Stefania Pittaluga, Samantha Simon, Damian Kovalovsky, Adrian Wiestner, Matthew G. Cyr, Jeong Heon Yoon, Christoph Rader, Julie Alejo, Ronald E. Gress
Publikováno v:
Leukemia
The only current curative treatment for chronic lymphocytic leukemia (CLL) is allogenic hematopoietic stem cell transplantation. Chimeric antigen receptor treatment targeting CD19 for CLL achieved some complete responses, suggesting the need for alte
Autor:
Yong-Jun Liu, Jodi L. Karnell, Santosh K. Panda, Miguel A. Sanjuan, Shino Hanabuchi, Elisaveta Voynova, Rachel Ettinger, Richard N. Hanna, Roland Kolbeck, Valeria Facchinetti
Publikováno v:
Journal of Clinical Investigation. 128:1873-1887
Uncontrolled secretion of type I IFN, as the result of endosomal TLR (i.e., TLR7 and TLR9) signaling in plasmacytoid DCs (pDCs), and abnormal production of autoantibodies by B cells are critical for systemic lupus erythematosus (SLE) pathogenesis. Th
Autor:
Lucas T. Woods, Helen Braley-Mullen, Gary A. Weisman, Elisaveta Voynova, Tamer I. Mahmoud, Rachel Ettinger
Publikováno v:
ImmunoHorizons
CD40/CD40L interactions play a critical role in immunity and autoimmunity. In this study, we sought to understand the requirement for CD40 signaling in the programmed cell death-1 (PD-1) checkpoint and CD28 costimulatory pathways important for mainte
Publikováno v:
The Journal of Immunology. 194:1503-1513
Chronic inflammatory conditions, such as in autoimmune disease, can disturb immune cell homeostasis and induce the expansion of normally rare cell populations. In our analysis of various murine models of lupus, we detect increased frequency of an unc
Autor:
Jodi L, Karnell, Varsha, Kumar, Jingya, Wang, Shu, Wang, Elisaveta, Voynova, Rachel, Ettinger
Publikováno v:
Cellular immunology. 321
A growing body of evidence suggests that when B cells are chronically stimulated, a phenotypically unique subset expands. Data suggest that this atypical population contains B cell receptor (BCR) specificities capable of binding the antigen, or sets
Autor:
Bethany Scott, Jonathan Deane, Elizabeth R. Walsh, Prapaporn Pisitkun, Elisaveta Voynova, Silvia Bolland, Rachel R. Caspi
Publikováno v:
Proceedings of the National Academy of Sciences. 109:16276-16281
Toll-like receptor 7 ( Tlr7 ) has been linked to systemic lupus disease incidence in humans and mice, but how TLR7 potentiates autoimmunity is unclear. We used a Tlr7 transgenic (tg) mouse model to investigate the cellular and molecular events requir
Autor:
Kalina Nikolova, Tchavdar L. Vassilev, Andrey Tchorbanov, Reinhard E. Voll, Nikolina Mihaylova, Elisaveta Voynova
Publikováno v:
Autoimmunity Reviews. 9:775-779
A novel approach for the selective silencing of targeted autoreactive B lymphocytes is reviewed that mimics the physiological mechanisms for suppressing B cell activity. It is based on the use of bi- or tri-specific chimeric antibodies that cross-lin